Ramos Alvarez C.,Helios Inc. |
Borhidi A.,University of Pecs
Acta Botanica Hungarica | Year: 2013
A new species of Guettarda is described, at this time it has been collected only in the type locality. It is similar to the Mesoamerican species G. tikalana Lundell. Source
Parkinson A.,Helios Inc.
2011 Tyrrhenian International Workshop on Digital Communications - Enhanced Surveillance of Aircraft and Vehicles, ESAV'11 | Year: 2011
This paper investigates the feasibility and merits of a space-based ADS-B system. The primary concept that will be investigated is the reception of ADS-B transmissions from aircraft in oceanic airspace using satellites and the subsequent relay of the data to end-users on the ground. © 2011 A.V.V.-Assoc Vito Violterra. Source
Binder C.,Helios Inc.
Internistische Praxis | Year: 2015
Wheat allergy is the fifth most common cause of food allergy in children. The prevalence of clinically significant wheat allergy is overestimated in the population. Furthermore, wheat allergy is often confused with celiac disease, as the layman may not be aware of the differences are not know. Due to parent insecurity many children are placed under dietary restrictions, where wheat is replaced by spelt. It is therefore vital to perform a detailed diagnosis with subsequent food challenges. Dietary restriction in wheat allergy is solely limited to the elimination of wheat, primal forms and products that contain wheat. The clinical relevance should be reviewed every 1-2 years. Source
[Quality management in psychiatry: evaluation of an ergotherapeutical questionnaire before and after treatment]. [Qualitätsmanagement der psychiatrischen Behandlung: Evaluation ergotherapeutischer Befundbögen bei Aufnahme und Entlassung.]
Sonntag A.,Helios Inc.
Versicherungsmedizin / herausgegeben von Verband der Lebensversicherungs-Unternehmen e.V. und Verband der Privaten Krankenversicherung e.V | Year: 2012
In analogy to somatic medicine, modern psychiatry strives to measure the outcome of treatment and care. In order to warrant an effective therapy, this request is reasonable from the standpoint of both the therapist and the patient as well as hospitals or insurance companies. However, how can I measure friendliness, empathy or humanity, the "being available for somebody"? For sure, psychiatric DRGs, which connote efficacy based on periods of time, are by no means suitable. The present study analyses routine clinical data of an ergotherapeutic questionnaire, as an aid to estimating treatment quality. The naturalistic character of this data collection during daily routine may be an advantage to assessing the quality of results in psychiatry. Source
Diel R.,Hannover Medical School |
Loaddenkemper R.,Helios Inc. |
Nienhaus A.,Institution for Statutory Accident Insurance and Prevention
Chest | Year: 2010
Test accuracy of interferon-γ release assays (IGRAs) for diagnosing TB differs when using older or precommerrial tools and inconsistent diagnostic criteria. This metaanalysis critically appraises studies investigating sensitivity and specificity of the commercial T-Spol.TB and the QuantiFERON-TB Cold In-Tube Assay (QFT-IT) among definitely confirmed TB cases. We searched Medline, EMBASE, and Cochrane bibliographies of relevant articles. Sensitivities, specificities, and indeterminate rates were pooled using a fixed effect model. Sensitivity of the tuberculin skin test (TST) was evaluated in the context of IGRA studies. In addition, the rates of indeterminates of both IGRAs were assessed. The pooled sensitivity of TST was 70% (95% CI, 0.67-0.72) compared with 81% (95% CI, 0.78-0.83) for the QFT-IT and 88% (95% CI, 0.85-0.90) for the T-Spot.TB. Sensitivity increased to 84% (95%CI, 0.81-0.87) and 89% (95% CI, 0.86-0.91) for the QFT-IT and T-Spot.TB, respectively, when restricted to performance in developed countries. In contrast, specificity of the QFT-IT was 99% (95% CI, 0.98-1.00) vs 86% for the T-Spot.TB (95% CI, 0.81-0.90). The pooled rate of indeterminate results was low, 2.1% (95% CI, 0.02-0.023) for the QFT-IT and 3.8% (95% CI, 0.035-0.042) for the T-Spot.TB, increasing to 4.4% (95% CI, 0.039-0.05) and 6.1% (95% CI, 0.052-0.071), respectively, among immunosuppressed hosts. The newest commercial IGRAs are superior, in comparison with the TST, for detecting confirmed active TB disease, especially when performed in developed countries. © 2010 American College of Chest Physicians. Source